The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Cancers · 31.03.2023 · 15 (7) · 2101
DOI: 10.3390/cancers15072101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 31.03.2023. Verfasst von Despoina E Kiousi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Faculty of Health Sciences, Democritus University of Thrace, 68100 Alexandroupolis, Greece. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Regional Development Fund, Operational Program “Competitiveness, Entrepreneurship & Innovation” (EPAnEK).
Abstract (Originalsprache)
Cancer immunotherapy is a treatment modality that aims to stimulate the anti-tumor immunity of the host to elicit favorable clinical outcomes. Immune checkpoint inhibitors (ICIs) gained traction due to the lasting effects and better tolerance in patients carrying solid tumors in comparison to conventional treatment. However, a significant portion of patients may present primary or acquired resistance (non-responders), and thus, they may have limited therapeutic outcomes. Resistance to ICIs can be derived from host-related, tumor-intrinsic, or environmental factors. Recent studies suggest a correlation of gut microbiota with resistance and response to immunotherapy as well as with the incidence of adverse events. Currently, preclinical and clinical studies aim to elucidate the unique microbial signatures related to ICI response and anti-tumor immunity, employing metagenomics and/or multi-omics. Decoding this complex relationship can provide the basis for manipulating the malleable structure of the gut microbiota to enhance therapeutic success. Here, we delve into the factors affecting resistance to ICIs, focusing on the intricate gut microbiome–immunity interplay. Additionally, we review clinical studies and discuss future trends and directions in this promising field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology and Genetics, Faculty of Health Sciences, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
- Oncology Department, 424 General Military Training Hospital, 56429 Thessaloniki, Greece.
- Oncology Department, Rhodes General Hospital, 85133 Rhodes, Greece.
ORCID-Profile: Emmanuel Karavanis, Aglaia Pappa, Alex Galanis
Förderung
- European Regional Development Fund
- Operational Program “Competitiveness, Entrepreneurship & Innovation” (EPAnEK)
Zitieren
APA
Kiousi, D. E., Kouroutzidou, A. Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., & Galanis, A. (2023). The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. Cancers, 15(7), 2101. https://doi.org/10.3390/cancers15072101
Vancouver
Kiousi DE, Kouroutzidou AZ, Neanidis K, Karavanis E, Matthaios D, Pappa A, et al. The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions. Cancers. 2023;15(7):2101. doi:10.3390/cancers15072101
BibTeX
@article{Kiousi2023,
author = {Kiousi, Despoina E and Kouroutzidou, Antonia Z and Neanidis, Konstantinos and Karavanis, Emmanuel and Matthaios, Dimitrios and Pappa, Aglaia and Galanis, Alex},
title = {The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions},
journal = {Cancers},
year = {2023},
volume = {15},
number = {7},
pages = {2101},
doi = {10.3390/cancers15072101}
}
EUVIMED